NCT05973643Recruiting
Metabolomics During ElectroConvulsivoTherapy
Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode
Source: ClinicalTrials.gov · Last updated 24 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Investigators will measure the variation of blood Metabolome through 1H NMR at several time points during the course of electroconvulsivetherapy in patients with a major depressive episode. Patients with a major depressive disorder or a bipolar disorder and a current major depressive episode will be included in this study. Investigators hypothesized that Metabolome could be a source to predict response during ECT and to help understanding underlying biological mechanisms.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 17 Jul 2023
- Start date
- 11 Mar 2024
- Primary completion date
- 15 Oct 2025
- Lead sponsor
- Hôpital le Vinatier
- Diseases
- Depression
- NCT number
- NCT05973643
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 11 Mar 2024 to the primary completion date, 15 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- suffering from an acute or chronic systemic inflammatory disease requiring specific treatment with immunomodulators or suppressors. As well as any recurrent inflammatory disease requiring specific management, and which may lead to a differential diagnosis of the characterized depressive episode as described by criterion C listed in the DSM-5
Other illness
- Suffering from schizophrenia spectrum disorders or persistent delusional disorder as described by DSM-5 Criterion D for Major Depressive Disorder
- suffering from neurological disorders (such as patients suffering from multiple sclerosis, epilepsy, encephalitis, etc.) and/or neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease or related diseases, etc.) as described by criterion C of the major depressive disorder listed in the DSM-5
Other
- whose consent is not admissible or who refuse to participate in the study
- deprived of liberty by judicial or administrative decision
- For which there is a particular risk contraindicating the cure of ECT
Who the study is looking for
- Major depressive episode according to DSM-5 criteria
- Diagnosis of major depressive disorder or bipolar disorder
- MADRS score \>22
- having given written, free and informed consent
- without protective measures
- resistance criterion defined as failure of 2 antidepressants at an effective dose for a minimum of 6 weeks
- current major depressive episode according to DSM-5 criteria with indication of treatment by ECT cure
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Le Vinatier Coordinator of this site? Confirm its status | Bron | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.